• E-ISSN 2636-7688
  • Call Us: +90 422 341 06 60 / 1224
  • Email Us: dergi@inonu.edu.tr

Formerly Journal of Turgut Ozal Medical Center - ISSN 1300-1744

  • Annals of Medical Research



    Annals of Medical Research International Monthly Published Medical Journal

  • Annals of Medical Research

    In publication or citation search, the name similarities of the authors, typographical errors and institutional changes can cause confusion. To prevent this, researchers need to obtain a descriptive ID. ORCID (Open Researcher and Contributor ID) is a researcher-specific international URI with a 16-digit number. You can register for free for individual ORCID at http://orcid.org. Please indicate the ORCID number of all authors when submitting your article.

  • Annals of Medical Research


    Annals of Medical Research indexed in TÜBİTAK/ULAKBİM Tıp Veri Tabanı

  • Annals of Medical Research


    Annals of Medical Research indexed in

  • Annals of Medical Research
  • Annals of Medical Research
  • Annals of Medical Research
  • Annals of Medical Research

Dear readers,

Our journal is the official publication of Inonu University Medical Faculty and published uninterruptedly for 25 years. It was first published as the name of Inonu University Medical Journal and later as Journal of Turgut Ozal Medical Center. During its publication period, the journal accepted Turkish or English articles for publication.

Abstracting in an international index is just a paramount objective in the 25th year of the journal. Because of this goal, it was necessary to make a decision both in terms of journal name and publication language. It was important in this respect that the name of a general medical journal should be related to medicine again and it should be in English. For these reasons, the name of the journal was switched to Annals of Medical Research and its publication language is changed to in English. The logo of the journal was chosen as an apricot, which is the symbol of our city Malatya, the world capital of apricot. I hope the journal succeeds with its new name. Annals of Medical Research is It is published monthly.

Editor-in-Chief
Cuneyt Kayaalp

 

Autoimmune hemolytic anemia in children, 20 years experience of single center (p.138-43)

Autoimmune hemolytic anemia in children, 20 years experience of single center (p.138-43)

Neslihan Karakurt1, Canan Albayrak1, Davut Albayrak2
1Ondokuz Mayis University, Faculty of Medicine, Department of Pediatrics, Division of Hematology, Samsun, Turkey
2Samsun Medical Park Hospital, Clinic of Pediatrics Hematology, Samsun, Turkey

Copyright © 2020 by authors and Annals of Medical Research Publishing Inc.

Abstract

Aim: Autoimmune hemolytic anemia (AIHA) is a rare disease in pediatrics, whose mortality rate was reported to be as high as 10%. AIHA can be primary or secondary to other diseases, Availability of new immunsupressive drugs like mycofenolate mofetil (MMF), has provided the opportunity to reduce long term steroid administration and mortality. In this study we aimed to represent AIHA patients of 20 years, from single centre and focus on the causes, treatment and outcomes. The secondary object was to represent outcomes of patients who received MMF.
Material and Methods: This study was designed as a retrospective study. Patients aged three months to 18 years old with hemoglobin level less than 10 g/dl and positive DAT with signs of hemolysis were included in the study.
Results: Twenty five AIHA patients (F/ M: 14/ 11) aged 6.2± 4.6 years old were followed- up for a mean period of 5.3± 4.8 years. Primary AIHA was detected in 12 (48%) patients. Immune deficiency/ autoimmune lymphoproliferative syndrome was the prominent etiological factor in secondary AIHA. The other underlying diseases were systemic lupus erythematosus, malignancy, autoimmune hepatitis and infection.
Eleven patients received MMF with a mean duration of 2.6± 1.6 years. Two of them had primary AIHA, the others had secondary disease. During the follow- up time, eight patients (75%) achieved remission with MMF. None of MMF users developed side effect.
One but all patients with AIHA achieved remission. No death related to AIHA was recorde': recorded
Conclusion: Understanding the biology of the disease and making accurate diagnosis is important to avoid harmful treatment and to consider targeted therapy. After the failure of first line therapy with steroids or as a steroid- sparing agent, MMF seems to be an effective second-line maintanance immunosuppressive drug without significant side effects.

Keywords: Autoimmune hemolytic anemia; pediatrics; mycofenolate mofetil

 

DOWNLOAD
doi: 10.5455/annalsmedres.2019.10.672

DownloadXML


Contact us

+90 422 341 06 60 / 1224 - University

+90 422 341 06 60 Department


Location

Inonu University Faculty of Medicine

Malatya, 44069

Turkey


Send us email

dergi@inonu.edu.tr

dergi@inonu.edu.tr


demo

Annals of Medical Research is the scientific official journal of the Inonu University Faculty of Medicine. It is published monthly. The essential aim of the Annals of Medical Research is to publish scientifically high quality clinical and experimental research articles on fields of medicine which can contribute to the literature data. In addition, review articles, case reports, editorials, letters to the editors and manuscripts on publication ethics and medical history, which can contribute to the education and practices of physicians and health sector professionals within the scope of the journal’s target audience and which can increase the level of scientific communication between the authors and readers, are included in the scope of the journal.

 

Recent News

Links

Certificate of General Impact Factor

Email Newsletter

Sign up for the latest Inonu University Our new article, updates....